View Older Stories View More Recent Stories

Apr 24, 2017 05:36AM Bristol-Myers Squibb (BMY) Reports Positive Phase 2 Data for BMS-986036 (Pegylated FGF21)
Apr 22, 2017 01:01AM Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Apr 21, 2017 02:07PM Bristol-Myers Squibb (BMY) Announces Positive CHMP Opinion Recommending Approval of Opdivo to Treat Locally Advanced or mUC
Apr 21, 2017 02:06PM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinom
Apr 17, 2017 06:59AM Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology
Apr 13, 2017 07:10AM Biogen (BIIB) Confirms Agreement to License Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb (BMY)
Apr 13, 2017 07:00AM Bristol-Myers Squibb (BMY) Enters Agreements to License Anti-eTau, Anti-Myostatin Compounds to Biogen (BIIB), Roche
Apr 13, 2017 07:00AM Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
Apr 13, 2017 06:59AM Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to License Anti-eTau and Anti-Myostatin Compounds, Respectively
Apr 11, 2017 07:00AM Bristol-Myers Squibb (BMY) Announces Collaboration with Apexigen for Opdivo Combination with APX005M
Apr 11, 2017 06:59AM Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
Apr 4, 2017 04:21PM Bristol-Myers Squibb (BMY) Confirms FDA Accepts Supplemental Biologics License Application (sBLA) to Extend use of Opdivo in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer
Apr 4, 2017 04:15PM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer
Apr 3, 2017 10:49AM Bristol-Myers Squibb (BMY) Says Opdivo CheckMate -143 Did Not Meet Primary Endpoint
Apr 3, 2017 10:47AM Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme
Apr 3, 2017 08:37AM Bristol-Myers Squibb (BMY) Announces First Report of 5-yr (OS) Data from Phase 1 Dose-Ranging Study CA209-003 Evaluating Opdivo
Apr 3, 2017 08:34AM Bristol-Myers Squibb (BMY) Announces First (OS) Data from the Phase 3 CheckMate -067 Clinical Trial
Apr 3, 2017 08:30AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma
Apr 3, 2017 08:30AM Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003
Apr 3, 2017 05:55AM Bristol-Myers Squibb (BMY) and Incyte (INCY) Advance Epacadostat and Opdivo Combo
Apr 2, 2017 06:59AM Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials
Mar 30, 2017 07:01AM Bristol-Myers Squibb (BMY), Foundation Medicine (FMI) Enter Pact to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Mar 30, 2017 06:59AM Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Mar 28, 2017 07:20AM Bristol-Myers Squibb (BMY), CRI, and Parker Institute for Cancer Immunotherapy Enter Research Pact
Mar 28, 2017 06:59AM Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research
Mar 24, 2017 08:33AM Bristol-Myers Squibb (BMY) Announces Positive CHMP Opinion of Opdivo for Treatment of SCCHN in Adults Progressing on or After Platinum-based Therapy
Mar 24, 2017 08:31AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Ther
Mar 20, 2017 07:01AM Bristol-Myers Squibb (BMY), CtomX Therapeutics (CTMX) Extend Strategic Collaboration
Mar 20, 2017 06:59AM Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases
Mar 17, 2017 11:17AM Bristol-Myers Squibb (BMY), Pfizer (PFE) Present Analysis of Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation
Mar 17, 2017 11:15AM Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial
Mar 10, 2017 10:20AM Bristol-Myers Squibb to Announce Results for First Quarter 2017 on April 27
Mar 8, 2017 12:26PM Bristol-Myers Squibb (BMY) Names Lynch EVP/CSO as Cuss Retires
Mar 8, 2017 12:24PM Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer
Mar 8, 2017 09:00AM Bristol-Myers Squibb to Take Part in Barclays Global Health Care Conference
Mar 6, 2017 08:34AM Bristol-Myers Squibb (BMY), Pfizer (PFE) to Present New Analyses of Eliquis and Real-World Data at ACC
Mar 6, 2017 08:30AM Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session
Mar 2, 2017 04:34PM Bristol-Myers Squibb Announces Dividend
Mar 1, 2017 06:20PM Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017
Mar 1, 2017 08:12AM Bristol-Myers Squibb (BMY) Announces Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening
Mar 1, 2017 08:10AM Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening
Feb 27, 2017 09:30AM Bristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global Health Care Conference
Feb 27, 2017 07:00AM Bristol-Myers Squibb (BMY) Adds Columbia University Medical Center and Peter MacCallum Cancer Centre to II-ON
Feb 27, 2017 07:00AM Exelixis (EXEL), Bristol-Myers Squibb (BMY) Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
Feb 27, 2017 06:59AM Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre
Feb 27, 2017 06:59AM Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
Feb 22, 2017 06:00PM Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes
Feb 21, 2017 07:01AM Bristol-Myers Squibb (BMY) Announces $2B Accelerated Share Repurchase and Names Three New Independent Directors in Agreement with JANA
Feb 21, 2017 06:59AM Bristol-Myers Squibb Appoints Three New Independent Directors
Feb 14, 2017 03:41PM JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
View More Recent Stories View Older Stories